SCHEMBL6748543

SCHEMBL6748543

CSc1cc(Cl)ccc1C(=O)CC(=O)C1CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERCC5 P28715 2/20 0.39
FEN1 P39748 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
FLT1 P17948 1/20 0.37
FLT4 P35916 1/20 0.37
KDR P35968 1/20 0.37
KMT2A Q03164 4/20 0.37
ALDH1A1 P00352 3/20 0.37
KDM4E B2RXH2 3/20 0.37
MEN1 O00255 3/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MAPK1 P28482 1/20 0.36
HIF1A Q16665 1/20 0.36
CTSK P43235 1/20 0.36
CCR2 P41597 1/20 0.36
MAPT P10636 3/20 0.36
HTT P42858 2/20 0.35
LMNA P02545 1/20 0.35
PLA2G1B P04054 1/20 0.35
HPGD P15428 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7177401 0.92 ERCC5 (0.34) ERCC5FEN1TDP1FLT1FLT4
SCHEMBL8488611 0.81 ERCC5 (0.59) ERCC5FEN1TDP1ALDH1A1KDM4E
SCHEMBL29391001 0.80 SLC6A9 (0.41) KMT2AALDH1A1KDM4EMEN1MAPK1
SCHEMBL8041947 0.80 THRA (0.32) MAPTHPGDTHRBNPC1
SCHEMBL6751338 0.80 SLC6A9 (0.41) KMT2AALDH1A1KDM4EMEN1MAPK1
SCHEMBL9073271 0.80 MAPT (0.35) ERCC5FEN1KMT2AALDH1A1KDM4E
SCHEMBL7554528 0.78 FLT1 (0.43) ERCC5FEN1FLT1FLT4KDR
SCHEMBL8492085 0.77 F10 (0.41) ERCC5FEN1FLT1FLT4KDR
SCHEMBL8389663 0.76 SMN1; SMN2 (0.36) ERCC5FEN1KMT2AALDH1A1KDM4E
SCHEMBL6746643 0.75 ERCC5 (0.36) ERCC5FEN1KMT2AALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6696613-B2 REACTING NITROHALOBENZENE DERIVATIVE WITH NITROETHANE IN PRESENCE OF A BASE SELECTED FROM THE GROUP CONSISTING OF A HYDROXIDE, A CARBONATE, A HYDRIDE, AN ALKOXIDE OF AN ALKALI OR ALKALINE EARTH METAL, AND GUANIDINE AND SOLVENT RHONE POULENC AGROCHIMIE (FR) 2004-02-24 US disclosed
US-6525225-B2 Reacting a nitro-substituted acetophenone with (1) a mercaptan to replace the nitro group with an alkyl- or phenyl-thio group; or (2) nitroethane to replace the acetyl group with a 1-nitroethyl group RHONE POULENC AGROCHIMIE (FR) 2003-02-25 US disclosed
US-20020062045-A1 Process for preparing diketone compounds and precursors thereto PEVERE VIRGINIE (FR) 2002-05-23 US disclosed
EP-0880498-B1 PROCESS FOR PREPARING DIKETONE COMPOUNDS AVENTIS CROPSCIENCE SA (FR) 2001-11-21 EP disclosed
US-20010014761-A1 Process for preparing diketone compounds and precursors thereto PEVERE VIRGINIE (FR) 2001-08-16 US disclosed
US-6235942-B1 REACTION OF KETONE WITH CYCLOPROPANECARBOXYLIC ESTER TO FORM DIKETONE RHONE-POULENC AGROCHIMIE (FR) 2001-05-22 US disclosed
EP-0880498-A2 PROCESS FOR PREPARING DIKETONE COMPOUNDS RHONE-POULENC AGROCHIMIE (FR) 1998-12-02 EP disclosed
WO-1997028122-A2 PROCESS FOR PREPARING DIKETONE COMPOUNDS RHONE-POULENC AGROCHIMIE (FR) 1997-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010014761-A1 Process for preparing diketone compounds and precursors thereto KMO, DHCR7, KHK ERCC5 2133/4885FEN1 4278/4885TDP1 3949/4885
US-20020062045-A1 Process for preparing diketone compounds and precursors thereto KMO, DHCR7, KHK ERCC5 2133/4885FEN1 4278/4885TDP1 3949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.